Product Information
JCN037 is a potent, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor in clinical development for the treatment of malignant brain tumors. JCN037 has been shown to potently inhibit EGFR tyrosine kinase activity in vitro and in vivo, with an IC50 of 0.2 nM and 1 nM respectively. JCN037 has a high affinity for the EGFR, with a Kd of 2.5 nM and it inhibits EGFR-mediated signaling by binding to the ATP site on the EGFR protein. The selectivity profile of JCN037 was characterized by its ability to inhibit tyrosine kinases other than EGFR with an IC50 >100 μM. This molecule also blocks tumor cell proliferation by inhibiting downstream signaling pathways such as epidermal growth factor (EGF) receptor activation and phosphorylation of ERKs and Akt, which are important molecules involved in cell
Chemical properties
Technical inquiry about: 3D-FSD15431 JCN037
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
